Investors & Media

Investors & Media

About Immatics

Immatics combines the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors with the goal of enabling a robust and specific T cell response against these targets. This deep know-how is the foundation for our pipeline of Adoptive Cell Therapies and TCR Bispecifics as well as our partnerships with global leaders in the pharmaceutical industry. We are committed to delivering the power of T cells and to unlocking new avenues for patients in their fight against cancer. 

 

Stock Quote

Immatics N.V.

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Press & Media

Immatics veröffentlicht Ergebnisse des dritten Quartals 2022 sowie ein Update zur Geschäftsentwicklung

read more

Immatics gibt garantiertes öffentliches Zeichnungsangebot von Stammaktien im Wert von $110 Millionen bekannt

read more

Immatics veröffentlicht Daten aus laufender Phase-1-Zelltherapie-Studie ACTengine® IMA203 TCR-T-Monotherapie gegen die Zielstruktur PRAME

read more